289 related articles for article (PubMed ID: 28814387)
1. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
Jacob D; Busciglio I; Burton D; Halawi H; Oduyebo I; Rhoten D; Ryks M; Harmsen WS; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G505-G510. PubMed ID: 28814387
[TBL] [Abstract][Full Text] [Related]
2. Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health.
Halawi H; Camilleri M; Acosta A; Vazquez-Roque M; Oduyebo I; Burton D; Busciglio I; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G442-G447. PubMed ID: 28774870
[TBL] [Abstract][Full Text] [Related]
3. Influence of a neurokinin-1 receptor antagonist (aprepitant) on gastric sensorimotor function in healthy volunteers.
Ang D; Pauwels A; Akyuz F; Vos R; Tack J
Neurogastroenterol Motil; 2013 Dec; 25(12):e830-8. PubMed ID: 23991829
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: a single-centre, randomised, controlled trial of tradipitant on satiation, gastric functions, and serum drug levels in healthy volunteers.
Khanna L; Zheng T; Atieh J; Torres M; Busciglio I; Carlin JL; Xiao M; Harmsen WS; Camilleri M
Aliment Pharmacol Ther; 2022 Jul; 56(2):224-230. PubMed ID: 35644931
[TBL] [Abstract][Full Text] [Related]
5. Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial.
Brandler J; Miller LJ; Wang XJ; Burton D; Busciglio I; Arndt K; Harmsen WS; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G635-G645. PubMed ID: 32036693
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans.
Madsen JL; Fuglsang S
Aliment Pharmacol Ther; 2008 Apr; 27(7):609-15. PubMed ID: 18208572
[TBL] [Abstract][Full Text] [Related]
7. Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers.
Castillo EJ; Delgado-Aros S; Camilleri M; Burton D; Stephens D; O'Connor-Semmes R; Walker A; Shachoy-Clark A; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2004 Aug; 287(2):G363-9. PubMed ID: 15246968
[TBL] [Abstract][Full Text] [Related]
8. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans.
Foxx-Orenstein A; Camilleri M; Stephens D; Burton D
Gut; 2003 Nov; 52(11):1555-61. PubMed ID: 14570722
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers.
Talley NJ; Camilleri M; Burton D; Thomforde G; Koch K; Rucker MJ; Peterson J; Zinsmeister AR; Earnest DL
Aliment Pharmacol Ther; 2006 Sep; 24(5):859-67. PubMed ID: 16918891
[TBL] [Abstract][Full Text] [Related]
10. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study.
Esfandyari T; Camilleri M; Ferber I; Burton D; Baxter K; Zinsmeister AR
Neurogastroenterol Motil; 2006 Sep; 18(9):831-8. PubMed ID: 16918762
[TBL] [Abstract][Full Text] [Related]
11. Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial.
Bouras EP; Talley NJ; Camilleri M; Burton DD; Heckman MG; Crook JE; Richelson E
Am J Gastroenterol; 2008 Aug; 103(8):2043-50. PubMed ID: 18803000
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers.
Choung RS; Talley NJ; Peterson J; Camilleri M; Burton D; Harmsen WS; Zinsmeister AR
Neurogastroenterol Motil; 2007 Mar; 19(3):180-7. PubMed ID: 17300287
[TBL] [Abstract][Full Text] [Related]
13. Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.
Nelson AD; Camilleri M; Acosta A; Busciglio I; Linker Nord S; Boldingh A; Rhoten D; Ryks M; Burton D
Neurogastroenterol Motil; 2016 Nov; 28(11):1705-1713. PubMed ID: 27283792
[TBL] [Abstract][Full Text] [Related]
14. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
15. Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study.
Delgado-Aros S; Camilleri M; Castillo EJ; Cremonini F; Stephens D; Ferber I; Baxter K; Burton D; Zinsmeister AR
Clin Gastroenterol Hepatol; 2005 Oct; 3(10):997-1006. PubMed ID: 16234046
[TBL] [Abstract][Full Text] [Related]
16. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.
Delgado-Aros S; Kim DY; Burton DD; Thomforde GM; Stephens D; Brinkmann BH; Vella A; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2002 Mar; 282(3):G424-31. PubMed ID: 11841992
[TBL] [Abstract][Full Text] [Related]
17. Effect of somatostatin analog on postprandial satiation in obesity.
Cremonini F; Camilleri M; Gonenne J; Stephens D; Oenning L; Baxter K; Foxx-Orenstein A; Burton D
Obes Res; 2005 Sep; 13(9):1572-9. PubMed ID: 16222060
[TBL] [Abstract][Full Text] [Related]
18. Associations of gastric volumes, ingestive behavior, calorie and volume intake, and fullness in obesity.
Vijayvargiya P; Chedid V; Wang XJ; Atieh J; Maselli D; Burton DD; Clark MM; Acosta A; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2020 Aug; 319(2):G238-G244. PubMed ID: 32628074
[TBL] [Abstract][Full Text] [Related]
19. A preliminary candidate genotype-intermediate phenotype study of satiation and gastric motor function in obesity.
Papathanasopoulos A; Camilleri M; Carlson PJ; Vella A; Nord SJ; Burton DD; Odunsi ST; Zinsmeister AR
Obesity (Silver Spring); 2010 Jun; 18(6):1201-11. PubMed ID: 19876010
[TBL] [Abstract][Full Text] [Related]
20. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
